Best of Precision and Immuno-Oncology Conference 2025
Event Landscape
Join co-chairs Dr. Heather McArthur and Dr. Marcus Butler at The Best of Precision and Immuno-Oncology Conference for a comprehensive exploration of the latest data in precision targeted therapies and immuno-oncology. This premier scientific event will empower clinicians to enhance diagnostic accuracy, refine treatment selection, and apply new evidence-based strategies to manage cancer patients. Leveraging emerging immuno-oncology therapies and the latest diagnostic technologies, attendees will gain the tools to personalize and tailor their therapies to optimize care. Sessions will cover a variety of important topics examining advances that pertain to clinical practice, adverse event management and novel therapies.
Learning Objectives
- Assess precision targeted therapies and immunological interventions for personalized cancer treatment.
- Analyze patient selection strategies and management of adverse events in precision and immuno-oncology.
- Apply evidence-based diagnostic and therapeutic approaches to optimize patient care.
Event Co-Chairs
Dr. Marcus Butler
MD
Marcus Butler is a physician investigator with an interest in the translational development of immune-based therapies for cancer patients. He completed his Hematology/Oncology training at Dana-Farber/Partners CancerCare, Harvard Medical School, Boston. After serving on the Dana-Farber staff, he joined the Department of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in 2012. He is a member of the medical oncology staff at Princess Margaret Cancer Centre, University Health Network, and Assistant Professor in Medicine and Immunology at the University of Toronto. He is the Melanoma/Skin Medical Oncology Site Lead at the Princess Margaret and is the Clinical Director for the Immune Profiling Team at the Princess Margaret. He is also the Medical Oncology Chair for the Melanoma Site for the Canadian Cancer Trials Group. His work focuses on the development of immunotherapy trials, which include studies, alone and in combination, of immune checkpoint blocking antibodies, immunomodulators, and adoptive cell transfer.
Dr. Heather McArthur
MD, MPH
Dr. Heather McArthur is the Clinical Director of Breast Cancer and the Komen Distinguished Chair in Clinical Breast Research at UT Southwestern (UTSW) Medical Center in Dallas. As a medical oncologist, she is dedicated to advancing the diagnosis and treatment of breast cancer, with a special focus on immune therapy innovations. Her research includes exploring the use of cryoablation or radiation with immune stimulation in early-stage breast cancer, with the hope of harnessing the immune system to develop long-term immunity against cancer. Dr. McArthur trained in medical oncology in Canada and completed an advanced fellowship at Memorial Sloan Kettering Cancer Center (MSKCC), where she subsequently joined the faculty and developed the institutional breast cancer immunotherapy program. She later joined Cedars-Sinai Medical Center in Los Angeles before coming to UTSW in 2021. She also holds a Master’s in Public Health from Harvard University, focusing on clinical trial design, and has guided numerous trainees in research projects. Dr. McArthur serves on multiple committees and task forces for prominent organizations such as the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) and the Society for Immunotherapy of Cancer (SITC). She is a recognized clinical trialist and is currently the global PI of three randomized phase 3 studies of immune therapy for the treatment of breast cancer.
Registrant Accommodations
As a registrant of the 19th Canadian Melanoma Conference we are pleased to offer you the CMC discounted room rate for your stay between February 16 – 26, 2025. Reservations will be accepted up to January 17, 2025 and will sell out quickly.
Abstract Submission Guidelines & Requirements
Residents, Students and fellows are invited to submit an abstract of their research between September 22 and November 22, 2024. All selected poster presenters (Lead Author) will have their conference registration fee waived. The reviewing committee will select 5 abstracts from those submitted for oral presentation; the latter is scheduled for in-person poster presentation at the Canadian Melanoma Conference in Vancouver, BC. One author for each of the 5 selected abstracts will receive a $3,000 CAD honorarium to assist with accommodations and travel to and from the conference.
2024 Important Dates:
Submission Opens: Sunday, September 22, 2024
Submission Deadline: Friday, November 22, 2024
Notification Sent to Lead Author: Friday, November 29, 2024
Please refer to the attachment linked below for submission guidelines and requirements.
Guidelines:
Sponsorship
For sponsorship-related inquiries, please contact your Director of Strategic Partnerships or visit our website
PLATINUM SPONSORS
GOLD SPONSORS
SILVER SPONSORS
All sales are final, refunds will not be accepted.
Please note mdBriefCase Group Inc. O/A Oncology Education cannot provide visa support for event attendees, including letters of invitation. Event attendees are solely responsible for obtaining any necessary documentation required for travel and participation in the event. No refunds shall be provided to individuals who are unable to attend.
Please be advised that video and photo recording will take place during this event. By registering and attending, you consent to being photographed and filmed. These materials may be used for promotional purposes, including but not limited to social media, websites, and other communication channels. If you have any concerns or wish to discuss this further, please contact us at [email protected] before the event.
